Cytochrome P450 2D6 Inhibitors

Cytochrome P450 17A1 Inhibitors

Cytochrome P450 17A1 Inhibitor

Cytochrome P450 2C8 Inhibitors

Prostatic Neoplasms, Castration-Resistant

<section class="Section" data-sectioncode="34089-3"><a name="ID_185c6935-4244-4d62-936a-fa1d8df5ee61"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION </h1><p class="First">Abiraterone acetate, the active ingredient of YONSA tablet is the acetyl ester of abiraterone. Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each YONSA Tablet contains 125 mg of abiraterone acetate. Abiraterone acetate is designated chemically as (3β)-17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate and its structure is:</p><div class="Figure"><img alt="image description" src="yonsa-1.jpg"/></div><p>Abiraterone acetate is micronized (smaller particle size) white to off-white, non-hygroscopic, crystalline powder. Its molecular formula is C<span class="Sub">26</span>H<span class="Sub">33</span>NO<span class="Sub">2</span> and it has a molecular weight of 391.55. Abiraterone acetate is a lipophilic compound with an octanol-water partition coefficient of 5.12 (Log P) and is practically insoluble in water. The pKa of the aromatic nitrogen is 5.19.</p><p>Inactive ingredients in the tablets are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, sodium stearyl fumarate, butylated hydroxyanisole, butylated hydroxytoluene.</p></section>

YONSA

abiraterone acetate

abiraterone

abiraterone acetate 125 MG Oral Tablet

Yonsa

abiraterone acetate 125 MG Oral Tablet [Yonsa]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity

Enroll in Patient Savings Program 

Other HCP Resources

About Yonsa

Taking Yonsa

Treatment Impact

Patient Resources

Doctor Discussion Guide

Instructions For Use: Prostate Cancer 